Study identifier:ALXN1920-HV-101
ClinicalTrials.gov identifier:NCT05751642
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase 1, Randomized, Double-blind, Placebo-controlled, Single Ascending Dose Study of Subcutaneously and Intravenously Administered ALXN1920 in Healthy Adult Participants
Healthy Participants
Phase 1
Yes
-
All
48
Interventional
18 Years - 55 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Sequential Assignment
Masking: -
Primary Purpose: Basic Science
Verified 01 Jan 2024 by Alexion Pharmaceuticals, Inc.
Alexion Pharmaceuticals, Inc.
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Cohort 1 Participants will receive a single dose of ALXN1920. | Biological/Vaccine: ALXN1920 Participants will receive a single dose of ALXN1920 by Subcutaneous (SC) injection. |
Experimental: Cohort 2 Participants will receive a single dose of ALXN1920. | Biological/Vaccine: ALXN1920 Participants will receive a single dose of ALXN1920 by Subcutaneous (SC) injection. |
Experimental: Cohort 3 Participants will receive a single dose of ALXN1920. | Biological/Vaccine: ALXN1920 Participants will receive a single dose of ALXN1920 by SC infusion. |
Experimental: Cohort 4 Participants will receive a single dose of ALXN1920. | Biological/Vaccine: ALXN1920 Participants will receive a single dose of ALXN1920 by SC infusion. |
Experimental: Cohort 5 Participants will receive a single dose of ALXN1920. | Biological/Vaccine: ALXN1920 Participants will receive a single dose of ALXN1920 by Intravenous (IV) infusion. |
Experimental: Cohort 6: Japanese Cohort Japanese participants will receive a single dose of ALXN1920. | Biological/Vaccine: ALXN1920 Participants will receive a single dose of ALXN1920 by SC infusion. |
Placebo Comparator: Pooled Placebo Participants will receive Placebo. | Biological/Vaccine: Placebo Participants will receive a single dose of Placebo by SC injection, SC infusion or IV infusion. |